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Background: Odontoblasts are specialized cells that form dentin and they are believed to be sensors for tooth pain.
Transforming growth factor-β1 (TGF-β1), a pro-inflammatory cytokine expressed early in odontoblasts, plays an
important role in the immune response during tooth inflammation and infection. TGF-β1 is also known to participate
in pain signaling by regulating cyclin-dependent kinase 5 (Cdk5) in nociceptive neurons of the trigeminal and dorsal
root ganglia. However, the precise role of TGF-β1 in tooth pain signaling is not well characterized. The aim of our
present study was to determine whether or not in odontoblasts Cdk5 is functionally active, if it is regulated by TGF-β1,
and if it affects the downstream pain receptor, transient receptor potential vanilloid-1 (TRPV1).
Results: We first determined that Cdk5 and p35 are indeed expressed in an odontoblast-enriched primary
preparation from murine teeth. For the subsequent analysis, we used an odontoblast-like cell line (MDPC-23) and
found that Cdk5 is functionally active in these cells and its kinase activity is upregulated during cell differentiation.
We found that TGF-β1 treatment potentiated Cdk5 kinase activity in undifferentiated MDPC-23 cells. SB431542, a
specific inhibitor of TGF-β1 receptor 1 (Tgfbr1), when co-administered with TGF-β1, blocked the induction of Cdk5
activity. TGF-β1 treatment also activated the ERK1/2 signaling pathway, causing an increase in early growth
response-1 (Egr-1), a transcription factor that induces p35 expression. In MDPC-23 cells transfected with TRPV1,
Cdk5-mediated phosphorylation of TRPV1 at threonine-407 was significantly increased after TGF-β1 treatment. In
contrast, SB431542 co-treatment blocked TRPV1 phosphorylation. Moreover, TGF-β1 treatment enhanced both
proton- and capsaicin-induced Ca2+ influx in TRPV1-expressing MDPC-23 cells, while co-treatment with either
SB431542 or roscovitine blocked this effect.
Conclusions: Cdk5 and p35 are expressed in a murine odontoblast-enriched primary preparation of cells from teeth.
Cdk5 is also functionally active in odontoblast-like MDPC-23 cells. TGF-β1 sensitizes TRPV1 through Cdk5 signaling in
MDPC-23 cells, suggesting the direct involvement of odontoblasts and Cdk5 in dental nociceptive pain transduction.
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Odontoblasts, the polarized columnar cells localized at
the periphery of the dental pulp, synthesize and secrete
collagenous and non-collagenous matrix proteins, such as
dentin sialophosphoprotein (DSPP), during dentinogene-
sis to form dentin [1]. Many growth factors, such as
transforming growth factor-β (TGF-β), fibroblast growth* Correspondence: ak40m@nih.gov
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reproduction in any medium, provided the orfactors (FGFs), and insulin-like growth factors (IGFs), are
believed to be mediators of the epithelial-mesenchymale
interactions involved in the functional differentiation of
odontoblasts [2]. In particular, TGF-β1, a prototype mem-
ber of the TGF-β superfamily, is expressed in a wide var-
iety of developing tissues from the earliest stages. TGF-β1
is also expressed in odontoblasts and ameloblasts during
the early stages of tooth development [3]. We previously
identified an important role for TGF-β signaling in the
mineralization and formation of dentin in mice over-
expressing TGF-β1 specifically in tooth [4]. We also dis-
covered that altered TGF-β1 expression in tooth impacts
the adhesion process of ameloblasts [5]. Interestingly,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Expression of Cdk5 and p35 in an odontoblast-
enriched preparation from murine teeth. Representative RT-PCR
analysis of Cdk5 and p35 mRNA levels in an odontoblast-enriched
preparation from murine teeth, TG and brain tissue. DSPP and DMP1
mRNA expression were used as odontoblast markers. Tau was used
as a neuronal marker and TRPV1 was used as a nociceptive neuron
marker. S29 was used as a housekeeping gene. RT- indicates
negative control.
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revealed vital roles for active TGF-β signaling in the regu-
lation of DSPP expression [6-8] and in cell migration
through activation of the p38 MAPK and AKT signaling
pathways [6].
However, the impact of TGF-β signaling on tooth pain
is far from clear. Tooth pain is mainly characterized by
the exposure of dentin to direct mechanical, chemical,
and/or thermal stimulation. Recent reports indicate that
odontoblasts express various family members of the
transient receptor potential (TRP) ion channels, such as
TRPV1, TRPV2, TRPV3, TRPV4, TRPA1, TRPM3, and
TRPM8. TRP channels are believed to participate in
the underlying molecular mechanisms involved in ther-
mal and mechanical sensory transduction [1,9-12]. Fur-
thermore, in functional assays using either cultured
odontoblast-like cells or native human odontoblasts,
specific agonists of either TRPV1, TRPA1, or TRPM8
elicited channel activation and transient influxes of
Ca2+ that could be blocked by their respective antago-
nists [11,13].
We previously discovered that cyclin-dependent kinase
5 (Cdk5), a proline-directed serine/threonine kinase,
plays a pivotal role in inflammatory pain [14-18]. Cdk5
kinase activity is predominant in post-mitotic neurons
where its activators, p35 and p39, are expressed, al-
though recently Cdk5 activity has also been detected
in non-neuronal tissues [19,20]. Increased expression of
p35, which occurred after experimentally-induced in-
flammation, was associated with elevated Cdk5 activity
in rat nociceptive primary afferent neurons [18]. We
also identified that Cdk5-mediated phosphorylation of
TRPV1 at Thr407 is involved in thermal nociception
and inflammatory pain [21]. We have further demon-
strated that tumor necrosis factor-α (TNF-α) increases
Cdk5 activity [16,17], while resveratrol, a polyphenolic
compound with known analgesic activity, inhibits Cdk5
activity [14]. Most importantly, we recently discovered
that TGF-β1 is a key regulator of Cdk5 activity in noci-
ceptive neurons, indicating that active crosstalk between
the TGF-β1 and Cdk5 pathways plays an important role
in inflammation-induced pain signaling [15]. However,
the role of similar crosstalk between TGF-β and Cdk5
has not been studied in relation to tooth pain, which is
frequently induced by inflammation associated with an
infection that affects odontoblast cells. Therefore, in the
current study, we have evaluated the expression of Cdk5
and p35 in both an odontoblast-enriched preparation
from murine teeth and in the odontoblast-like MDPC-
23 cell line. To evaluate its possible involvement in tooth
pain, we then characterized the regulation of Cdk5 activ-
ity by TGF-β1, detected the Cdk5-mediated phospho-
rylation of TRPV1, and finally measured its effect on
proton- and capsaicin-induced TRPV1 activation.Results
Expression of Cdk5 and p35 in an odontoblast-enriched
preparation from murine teeth
To determine whether mouse odontoblasts express
Cdk5 and p35, we extracted total RNA from an
odontoblast-enriched primary preparation from mouse
incisors and performed RT-PCR analysis. As a positive
control for Cdk5 and p35 expression, we used mouse
brain and trigeminal ganglion (TG). We found that
Cdk5 and p35 mRNAs are expressed in the odontoblast-
enriched preparation at levels similar to TG, but less
compared to brain (Figure 1). To evaluate the purity of
our odontoblast-enriched preparation, we analyzed the
expression of dentin sialophosphoprotein (DSPP) and
dentin matrix acidic phosphoprotein 1 (DMP1), two
well-characterized odontoblast markers. Interestingly, we
found DSPP expression only in the odontoblast-enriched
preparation, whereas DMP1 was found not only in our
odontoblast-enriched preparation but also in brain, con-
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expression of Tau, a neuronal marker, in our odontoblast-
enriched preparation. Interestingly, we found detectable ex-
pression of TRPV1 in our odontoblast-enriched prepar-
ation, but it was less robust as compared to TG. Taken
together, these results confirm the expression of Cdk5 and
p35, as well as TRPV1, in our odontoblast-enriched prepar-
ation from mouse incisors, implicating a potential role for
Cdk5 in tooth pain.
Differentiation of MDPC-23 cells induces activation of the
TGF-β signaling pathway
We previously reported that Cdk5 is a key player in
pain signaling [17,18]. TNF-α and TGF-β1 regulate
Cdk5 activity in sensory neurons by modulating the
expression of p35, a co-activator of Cdk5 [15,16]. To
investigate whether Cdk5 plays a similar role in tooth
pain signaling, we examined its expression and kinase
activity in MDPC-23 cells, an odontoblast-like cell
line derived from rodent dental papilla cells [23-25].
MDPC-23 cells can be induced to differentiate by
the addition of ascorbate (50 μg/ml) and β-glyce-
rophosphate (10 mM) to the culture medium. We ana-
lyzed the differentiation process of MDPC-23 cells by
observing cell morphology under a microscope; we
performed this daily for 5 days after starting the treat-
ment with ascorbate and β-glycerophosphate. We ob-
served the formation of multilayered nodules with
multiple cell membrane processes (data not shown),
similar to the phenotype described by others [23].
Moreover, it is also known that TGF-β1 regulates this
differentiation process [7]. We therefore evaluated the
activation of the TGF-β signaling pathway in MDPC-23
cells over 5 consecutive days of induced differentiation,
using Western blot analysis with antibodies directed
against phospho-Smad2 (Ser465/467) and total Smad2
(Figure 2A). We found that, as early as 2 days, phospho-
Smad2 levels increased significantly. Moreover, phospho-
Smad2 levels then remained elevated through the 5 day
course (Figure 2A).
Differentiation of MDPC-23 cells induces expression of
Cdk5 and p35, with a subsequent increase in Cdk5 kinase
activity
In order to address whether Cdk5 and p35 are expressed
in MDPC-23 cells, we conducted qPCR on total RNA
isolated from undifferentiated MDPC-23 cells and from
PC12 cells, a positive control for Cdk5 and p35 expres-
sion [16]. We found that Cdk5 and p35 mRNAs were
expressed in MDPC-23 cells at similar levels compared
to PC12 cells (data not shown). We then investigated
whether differentiation of MDPC-23 cells regulatesCdk5 and p35 expression. After 5 days of induced differ-
entiation, Cdk5 and p35 protein levels were analyzed by
Western blot analysis. We found that Cdk5 and p35
protein levels were significantly increased in differenti-
ated MDPC-23 cells as compared to undifferentiated
MDPC-23 cells (Figure 2B). Since the p35 protein level
is a limiting factor for Cdk5 kinase activity [26], we an-
alyzed whether the differentiation-mediated increase in
p35 expression results in an increase of Cdk5 activity.
We immunoprecipitated Cdk5 protein from the undiffer-
entiated and differentiated MDPC-23 cells using a Cdk5
antibody, and we then assayed Cdk5 kinase activity by
using histone H1 as a substrate. We found that Cdk5 kin-
ase activity was significantly increased in differentiated
versus undifferentiated MDPC-23 cells (Figure 2C).
TGF-β1 treatment increases p35 protein levels and Cdk5
kinase activity in MDPC-23 cells
We previously determined that TGF-β1 can regulate
Cdk5 kinase activity in sensory neurons through an in-
crease in p35 expression [15]. To evaluate whether the ac-
tivation of the TGF-β signaling pathway during the
differentiation process affects Cdk5 kinase activity in
MDPC-23 cells, we examined the effects of recombinant
TGF-β1 treatment on p35 expression and Cdk5 kinase ac-
tivity in undifferentiated MDPC-23 cells. We deprived
MDPC-23 cells of serum for 1 h and then treated these
cells with either vehicle (control), TGF-β1 (1 ng/ml),
Tgfbr1 inhibitor (SB431542, 10 μM), or TGF-β1 (1 ng/ml)
plus SB431542 (10 μM) for 0, 1, 2 and 3 h. We found that
1-3 h of TGF-β1 treatment resulted in a significant in-
crease of phospho-Smad2 (Ser465/467) levels. In contrast,
this effect was blocked in cells treated either with
SB431542 alone or TGF-β1 plus SB431542 (Figure 2E).
Most importantly, TGF-β1 treatment significantly in-
creased p35 mRNA levels as early as 1 h after treatment
and they remained elevated after 3 h of treatment as de-
termined by qPCR (Figure 2D). However, Cdk5 mRNA
levels were unchanged at each time point evaluated (data
not shown). Interestingly, p35 protein levels were also sig-
nificantly increased after 1 h of TGF-β1 treatment and
remained high at 3 h (Figure 2E) and 24 h (Figure 2F).
Cdk5 protein levels did not change after 0–3 h of TGF-β1
treatment (Figure 2E). In contrast, SB431542 treatment
with or without TGF-β1 totally blocked the increase of
p35 protein levels (Figure 2E), suggesting that activa-
tion of the TGF-β signaling pathway (via phosphory-
lation of Smad2) is essential for regulating p35 expression
in MDPC-23 cells.
Since p35 expression was induced by TGF-β1 treatment,
we evaluated whether Cdk5 kinase activity was also af-
fected in MDPC-23 cells. We found significantly increased
Cdk5 kinase activity after 24 h of TGF-β1 treatment
Figure 2 Differentiation or TGF-β1 treatment increases p35 expression and Cdk5 activity in MDPC-23 cells. A, Representative Western
blot analysis showing activation of the TGF-β1 signaling pathway, determined by an increase of phospho-Smad2, on successive days during
MDPC-23 cell differentiation. B, Upper panel shows a representative Western blot analysis of Cdk5 and p35 protein levels in undifferentiated (UD)
and 5-day differentiated (D) MDPC-23 cells. Lower panel shows quantification of the Western blot for Cdk5 and p35 in control cells and
differentiated MDPC-23 cells. C, Cdk5 kinase activity was measured from immunoprecipitates of control and 5-day differentiated MDPC-23 cells.
D, q-PCR analysis of p35 mRNA levels normalized against S29. Total RNA was obtained from MDPC-23 cells treated with TGF-β1
(1 ng/ml) for 0, 1, 2, and 3 h. E, Western blot analysis of phospho-Smad2, Smad2, p35, Cdk5, and α-tubulin was performed in MDPC-23 cells
treated with: vehicle (control), TGF-β1 (1 ng/ml), SB431542 (10 μM), and TGF-β1 (1 ng/ml) plus SB431542 (10 μM) over the course of 0, 1, 2, and
3 h. F, Quantification of Western blot of p35 and α-tubulin was performed in MDPC-23 cells treated with: vehicle (control), TGF-β1 (1 ng/ml),
SB431542 (10 μM) over 24 h. G, Cdk5 kinase activity measured from immunoprecipitates of MDPC-23 cells treated with vehicle (control),
SB431542 (0.1, 1, and 10 μM), TGF-β1 (1 and 10 ng/ml), and TGF-β1 (1 ng/ml) plus SB431542 (10 μM) over 24 h. All data are presented as the
mean and SEM (n = 3-5). * p < 0.05, ** p < 0.01; *** p < 0.001 (t-Test); a: p < 0.01 TGF-β1 treatment vs. control; and b: p < 0.01 TGF-β1 vs. TGF-β1
plus SB431542 treatment (Bonferroni’s test after ANOVA).
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ment (0.1, 1, and 10 μM) did not alter basal Cdk5 kinase
activity; however, co-treatment with TGF-β1 (1 ng/ml plus
10 μM SB431542) significantly blocked the TGF-β1-
mediated increase of Cdk5 kinase activity (Figure 2G).
Additionally, we analyzed whether roscovitine, a Cdk5inhibitor, would inhibit the Cdk5 kinase activity induced by
TGF-β1 in MDPC-23 cells. We found that basal Cdk5
kinase activity decreased in the presence of roscovitine
(25 μM) and, during co-treatment with TGF-β1 (1 ng/ml),
that roscovitine blocked the TGF-β1-mediated increase of
Cdk5 kinase activity (Figure 3D).
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ERK1/2 signaling pathway
It has been reported that several compounds, such as so-
dium fluoride (NaF) [27], amelogenin [28], or lipopolysac-
charide (LPS) [29], can activate the ERK1/2 signaling
pathway in MDPC-23 cells. The activation of the ERK1/2
signaling pathway was found to be crucial for regulating
p35 expression [14-16,30], and it has also been reported
that TGF-β1 can activate non-Smad signaling pathways
such as the ERK1/2 pathway [31]. Therefore, we evaluated
whether the ERK1/2 signaling pathway is affected during
the MDPC-23 differentiation process. We found that
levels of phospho-ERK1/2 (Thr202/Tyr204) were in-
creased after 2 days of differentiation and remained
elevated at each subsequent time point they were mea-
sured, while total ERK1/2 protein levels did not change
(Figure 3A). To evaluate whether TGF-β1 affects activa-
tion of the ERK1/2 signaling pathway, MDPC-23 undiffe-
rentiated cells were pre-treated with a specific MEK1
inhibitor, U0126 (20 μM), 30 min before adding TGF-β1
(1 ng/ml) for 0 to 3 h (Figure 3B). TGF-β1 increased
phospho-ERK1/2 levels at 1 to 3 h, and also increased p35
protein levels at these time points when compared toFigure 3 Differentiation or TGF-β1 treatment induces activation of th
A, Representative Western blot analysis showing activation of ERK1/2 signa
successive days during differentiation of MDPC-23 cells. B, Representative W
was performed in MDPC-23 cells treated with: vehicle (control), TGF-β1 (1 n
0, 1, 2, and 3 h. C, qPCR analysis of Egr-1 mRNA levels normalized against S
(1 ng/ml) for 0, 15, 30, 60, 120, and 180 min. D, The effect of roscovitine on
(control), SB431542 (10 μM), TGF-β1 (1 ng/ml), TGF-β1 (1 ng/ml) plus SB431
roscovitine (25 μM) over 24 h. E, Western blot analysis against Egr-1 from M
SB431542 (10 μM), and TGF-β1 (1 ng/ml) plus SB431542 (10 μM) over 24 h.
**p < 0.01, (Dunnett’s test after ANOVA).control cells. In contrast, when cells were co-treated with
U0126 (20 μM) and TGF-β1 (1 ng/ml), there was
complete inhibition of phospho-ERK1/2 at 0 to 3 h.
U0126 inhibited the p35 protein induction caused by 1 h
of TGF-β1 treatment but not after 2 or 3 h, where p35
protein levels increased similar to cells receiving only
TGF-β1 (Figure 3B). This suggests that the increase in
p35 protein, which we found in MDPC-23 cells to be me-
diated by TGF-β1, is in part dependent upon activation of
the ERK1/2 signaling pathway but likely also upon other
independent mechanisms as well.
We and others have reported that early growth
response-1 (Egr-1), an important transcription factor
that regulates p35 expression, is rapidly upregulated
after NGF or TNF-α treatment in PC12 cells [14,16,30],
and after TGF-β1 treatment in B104 rat neuroblastoma
cells [15]. Here, we evaluated whether Egr-1 mRNA ex-
pression is regulated by TGF-β1 treatment in undifferen-
tiated MDPC-23 cells by using qPCR. We found that
TGF-β1 (1 ng/ml) treatment produced a significant in-
crease in Egr-1 mRNA levels after 15 min, and these
levels remained elevated until 1 h but then decreased to
basal levels at 2 and 3 h (Figure 3C). Additionally, we founde ERK1/2 pathway and increases Cdk5 activity in MDPC-23 cells.
ling pathways measured by an increase in phospho-ERK1/2 on
estern blot analysis of phospho-ERK1/2, ERK1/2, p35, and α-tubulin
g/ml), and TGF-β1 (1 ng/ml) plus U0126 (20 μM) over the course of
29. Total RNA was obtained from MDPC-23 cells treated with TGF-β1
Cdk5 kinase activity. MDPC-23 cells were treated with vehicle
542 (10 μM), roscovitine (25 μM), and TGF-β1 (1 ng/ml) plus
DPC-23 cells treated with: vehicle (control), TGF-β1 (1 ng/ml),
All data are presented as the mean and SEM (n = 4). *p < 0.05,
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treatment (1 ng/ml), while co-treatment with SB431542
(10 μM) or SB431542 alone blocked the increase in
Egr-1 protein levels (Figure 3E). Collectively, these
results suggest that TGF-β1 induces a sustained and
robust increase in p35 levels, possibly through increased
Egr-1 expression.
TGF-β1 increases Cdk5-mediated phosphorylation of
TRPV1 and potentiates intracellular Ca2+ influx in MDPC-
23 cells
Odontoblast cells have been linked to dental nociception
[1,9,12,32] due to the expression of functional TRPV1
channels found in these cells from human [11] and
mouse [10]. We previously reported that Cdk5 can phos-
phorylate TRPV1, specifically at Thr407 [21]. Therefore,
we evaluated whether a TGF-β1-mediated increase in
Cdk5 activity could regulate phosphorylation of TRPV1
at Thr407 in MDPC-23 cells. The expression of TRPV1Figure 4 TGF-β1 potentiates Cdk5-mediated phosphorylation of TRPV
transiently transfected with the TRPV1-GFP plasmid vector after 48 h. After
TGF-β1 (1 ng/ml), and TGF-β1 (1 ng/ml) plus SB431542 (10 μM), and protein e
TRPV1, and α-tubulin 24 h later. B, Representative Western blot analysis showi
MDPC-23 cells treated with vehicle (control), TGF-β1 (1 ng/ml), and TGF-β1 (1
analysis against phospho-Thr407-TRPV1 in MDPC-23 cells treated with vehicle
over 24 h. D, Quantification analysis showed that TGF-β1 treatment significan
blocked this effect. All data are presented as the mean and SEM (n = 3). *p < 0has not been previously reported in MDPC-23 cells,
and we measured TRPV1 protein levels using Western
blot analysis but could not find detectable TRPV1 pro-
tein (data not shown). Therefore, we transiently
transfected MDPC-23 cells with a CMV promoter-
driven TRPV1-GFP vector [33]. After 24 h of transfec-
tion, MDPC-23 cells were treated with either vehicle
(control), TGF-β1 (1 ng/ml), or TGF-β1 (1 ng/ml) plus
SB431542 (10 μM), and protein extracts were analyzed
by Western blotting. We found the amount of GFP
fluorescence in transfected MDPC-23 cells remained
similar after all three treatments (Figure 4A). In addi-
tion, we evaluated the activation of TGF-β1 signaling
(phospho-Smad2 and total Smad2 protein levels) and
the expression of p35, Cdk5, GFP, TRPV1, and α-
tubulin after all three treatments using Western blot
analysis. We found that TGF-β1 treatment increased
phospho-Smad2 and p35 protein levels, and this in-
crease was blocked in cells co-treated with SB4315421 in MDPC-23 cells. A, Representative fluorescence of MDPC-23 cells
24 h of transfection, MDPC-23 cells were treated with vehicle (control),
xtracts were analyzed by Western blot against phospho-Thr407-TRPV1,
ng phospho-Smad2, Smad2, p35, Cdk5, GFP, TRPV1, and α-tubulin from
ng/ml) plus SB431542 (10 μM) over 24 h. C, Representative Western blot
(control), TGF-β1 (1 ng/ml), and TGF-β1 (1 ng/ml) plus SB431542 (10 μM)
tly increased phospho-Thr407-TRPV1 compared to control, and SB431542
.05, (t-Test).
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equivalent in all three treatment groups (Figure 4B). Most
importantly, we found that TGF-β1 treatment significantly
increased phospho-Thr407-TRPV1 levels when compared
to control cells, while phosphorylation of TRPV1 was
blocked in MDPC-23 cells co-treated with SB431542
(Figure 4C and D). These results suggest that in TRPV1-
expressing MDPC-23 cells, p35 protein levels increase in
response to TGF-β1, resulting in elevated Cdk5 activity
and TRPV1 phosphorylation.
To evaluate whether increased TRPV1 phosphorylation
in MDPC-23 cells treated with TGF-β1 has a physiological
effect, we examined proton- and capsaicin-induced cal-
cium influx in these cells (Figure 5A and B, respectively).Figure 5 TGF-β1 potentiates Cdk5-mediated phosphorylation of TRPV
cells. MDPC-23 cells stably transfected with rat TRPV1 were treated with as
without SB431542 (10 μM) or roscovitine (25 μM) over 24 h. We then exam
Ca2+ influx was stimulated with a pH 5.6 buffer (A) or with 100 nM capsaic
significantly following TGF-β1 treatment. In contrast, co-treatment with SB4
caused by the low pH buffer or by capsaicin. All data are presented as the
treatment; and b: p < 0.05 TGF-β1 vs. TGF-β1 plus roscovitine treatment (t-TCa2+ influx was measured in MDPC-23 cells stably
transfected with rat TRPV1 cDNA, and then these cells
were activated either with low pH buffer (Figure 5A) or
with 100 nM capsaicin (Figure 5B) in the presence of
calcium-45 (45Ca+2). Confluent cells were pre-treated
with TGF-β1 (0.1 to 3.0 ng/ml) alone, TGF-β1 in the
presence of SB431542 (10 μM), or TGF-β1 in the pres-
ence of roscovitine (25 μM), then cells were assayed for
calcium uptake at 24 h. We found enhanced calcium
uptake by cells treated with TGF-β1, compared to un-
treated control cells (dashed line at “100%” in Figure 5A
and 5B), and this effect was blocked when cells were co-
treated with either roscovitine or SB431542. Therefore,
these results suggest that TGF-β1-mediated phospho-1, resulting in increased intracellular Ca2+ influx in MDPC-23
cending concentrations of TGF-β1 (0.1, 0.3, 1, and 3 ng/ml), with or
ined both proton- and capsaicin-induced calcium influx in these cells.
in (B). The total influx of calcium under both conditions increased
31542 or roscovitine produced a significant decrease in calcium influx
mean and SEM (n = 3). a: p < 0.05 TGF-β1 vs. TGF-β1 plus SB431542
est). ns: not significant.
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induced Ca2+ influx in TRPV1-expressing MDPC-23 cells.
Discussion
We posed three main questions in this study: 1) Do
odontoblasts and the odontoblast-like MDPC-23 cells
express functional Cdk5/p35; 2) If yes, is there a cross-
talk between Cdk5 and the TGF-β signaling pathway;
3) Does the crosstalk have an impact on nociceptors,
specifically TRPV1. These three questions are crucial
for determining the potential role of Cdk5/p35 in
nociception and pain transduction by odontoblasts. Our
results clearly demonstrate that Cdk5 and p35 are
expressed in an odontoblast-enriched preparation from
murine teeth as well as in the odontoblast-like MDPC-
23 cell line. We found that Cdk5 kinase is active in
MDPC-23 cells. In addition, Cdk5 and p35 protein
levels, and Cdk5 kinase activity, increased in MDPC-23
cells during differentiation. Interestingly, the TGF-β and
ERK1/2 signaling pathways were activated during the
differentiation process, suggesting that Cdk5 activity is
regulated by TGF-β1 and ERK1/2 in these cells. Further-
more, we found that TGF-β1 treatment of MDPC-23
cells increased the mRNA and protein levels of p35,
resulting in a subsequent increase in Cdk5 kinase
activity. A Tgfbr1 inhibitor, SB431542, blocked this ef-
fect. We also found that Cdk5-mediated phosphorylation
of TRPV1 was significantly increased by TGF-β1 treat-
ment, while co-treatment with SB431542 again blocked
this effect. TGF-β1 treatment potentiated proton- and
capsaicin-induced Ca+2 influx in MDPC-23 cells stably
transfected with TRPV1, while SB431542 and roscovitine
inhibited this effect. Collectively, our results indicate
that Cdk5/p35 may play an important role in odonto-
blast function, specifically in relation to nociception.
Odontoblasts form a layer of specialized cells localized
directly beneath dentin, separating the dentin from tooth
pulp. Because of the morphological shape of odon-
toblasts, they are believed to play a pivotal role in
nociception. Odontoblast cells have a cellular process
that extends into a liquid phase (dentinal fluid) in calci-
fied tubules. Thus, odontoblasts are able to sense both
external stimuli and transient changes in the pulp micro-
circulation [32]. But currently, there are three prevailing
theories regarding the mechanism underlying dental
nociception: 1) neural, 2) hydrodynamic, or 3) odonto-
blastic. Of the three, the hydrodynamic theory is the
most widely accepted [34]. However, the odontoblastic
mechanism is gaining attention due to a recent finding
on the capacity of these cells to generate action poten-
tials [35], and to their functional expression of several
family members of the TRP ion channels [1,9-13,32,36],
as well as the TREK-1 channel [37]. In addition, dental
pulp expresses both ATP receptors [38] and ecto-ATPaseNTPDase2, one of the principal enzymes responsible for
extracellular ATP hydrolysis, suggesting the presence of
an apparatus for ATP release and degradation in human
dental pulp [39]. Our findings on the expression of Cdk5
and p35 in odontoblast-like cells, and on the regulation of
Cdk5 kinase activity by TGF-β1, support the theory that
odontoblasts are directly involved in dental nociception
and pain transduction.
We and others have delineated a role for Cdk5 in
sensory neurons during inflammatory hyperalgesia
[14-18,21,40-44]. Cdk5 has also been shown to be in-
volved in trigeminal neuropathic pain [45]. However,
there are no studies describing the expression or func-
tion of Cdk5 in odontoblast cells. Several functions have
already been described for Cdk5 and p35 in non-
neuronal cells [19,20,46]. We demonstrate here for the
first time that Cdk5 and p35 are expressed in an
odontoblast-enriched extract from murine teeth as well
as in odontoblast-like MDPC-23 cells. Moreover, TGF-
β1 treatment increases Cdk5 kinase activity in MDPC-23
cells, suggesting that Cdk5/p35 might participate in sev-
eral functions, but particularly in nociception. We previ-
ously demonstrated a key function for TGF-β1 during
odontoblast differentiation, where it down regulates
DSPP expression in mice that over-express TGF-β1 spe-
cifically in teeth [4]. Likewise, we found that TGF-β1
also participates in tooth mineralization, impacting the
adhesion of ameloblasts to dentin [5]. Moreover, TGF-β1
activates the Smad3 signaling pathway to down regu-
late DSP [7] and is important during migration of
odontoblast-like MDPC-23 cells [6]. TGF-β1 has also
been associated with facial pain, since TGF-β1 levels
were found to be significantly elevated in the plasma
and cerebrospinal fluid of migraineurs [47,48]. Most im-
portantly, we recently discovered that mice deficient in
TGF-β1 signaling have decreased Cdk5 kinase activity
and diminished TRPV1 phosphorylation in the trigemi-
nal and dorsal root ganglia, suggesting that an active
crosstalk between the TGF-β1 and Cdk5 signaling path-
ways impacts peripheral inflammatory pain [15]. Here,
we have identified potential involvement of TGF-β1 and
Cdk5 in dental nociception.
There is accumulating body of evidence that supports
our findings. From one study, the number of TGF-β1
positive cells was significantly increased during pulpitis
in the human odontoblast layer (ODL) [49,50]. Another
report showed that several cytokines, chemokines, and
their receptors, were upregulated in human ODL during
tooth caries [51], which are essentially caused by bacteria
and yeast that colonize dentin and root cementum [52].
Additionally, it was shown that immunoreactivity for
TGF-β1 was significantly increased in the odontoblast
and pulpal cells of carious teeth [53]. These findings
indicate that TGF-β1 is upregulated in normal patho-
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suggesting that TGF-β1 is vital not only in resolving in-
flammation and promoting wound healing, but also
likely involved in pain signaling. Based on our studies,
we propose a model where TGF-β1 is secreted during
bacterial inflammation and promotes Cdk5 kinase activ-
ity in odontoblasts. This in turn leads to the phosphoryl-
ation of TRPV1, other TRP ion channels, or TREK-1
channels, which then potentiates calcium influx during
stimulation. The subsequent depolarization caused by
calcium influx activates downstream effectors, possibly
leading to transmitter release from odontoblasts and
pain signal transmission (Figure 6).
Conclusions
Primary odontoblasts and odontoblast-like MDPC-23
cells express functional Cdk5/p35. TGF-β1 treatment in-
creases Cdk5 activity in TRPV1-expressing MDPC-23
cells. This subsequently leads to increased TRPV1 phos-
phorylation, thereby potentiating proton- and capsaicin-
induced calcium influx in these cells. Odontoblasts are
therefore suggested to be directly involved in dental
nociception, which can be modulated by Cdk5.
Methods
Materials
Tgfbr1 inhibitor (SB431542), DMSO, ascorbate, β-
glycerophosphate, histone H1, roscovitine, and α-tubulin
antibody were obtained from Sigma (St. Louis, MO).
MEK1 inhibitor (U0126) was obtained from Cell Signaling
Technology (Beverly, MA). Recombinant TGF-β1 was
obtained from R&D Systems (Minneapolis, MN). Protein
quantification reagents were obtained from Bio-Rad
Laboratories (Hercules, CA), and enhanced chemilumin-
escence reagents for Western blot analysis were purchased
from Thermo Scientific (Rockford, IL).
Antibodies
Antibodies to Cdk5, p35, Egr-1, TRPV1, and secondary
antibodies (HRP-conjugated goat anti-mouse, anti-rabbit
antibodies) were obtained from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA). Anti-phospho-Thr407-TRPV1 anti-
bodies were generated previously [21]. Antibodies to
phospho-ERK1/2 (Thr202/Tyr204) and total ERK1/2 were
obtained from Cell Signaling Technology (Beverly, MA).
Antibodies to phospho-Smad2 (Ser465/467) were ob-
tained from Millipore (Temecula, CA). Antibodies to
total Smad2 were obtained from Zymed (Invitrogen,
Carlsbad, CA).
Odontoblast-enriched preparation from murine teeth
All animal procedures were conducted in agreement
with NIH Standards, and approved by the Bioethics
Committee of the Faculty of Science, University of Chile,for the care and handling of laboratory animals. Six-
week old mice with C57/FVB/N6 genetic background
were euthanized and after decapitation, brain and TG
tissues were removed and stored at −80°C. Odontoblast-
enriched preparations from murine teeth were obtained
as previously reported [54]. Briefly, after removal of the
upper jaw including the incisors, the gingiva and peri-
odontal connective tissues were dissected along the
tooth surface. Connective tissues and blood adhering to
the outside of the teeth were carefully removed with a
blade and the teeth were suspended in cold saline in a
petri dish. Incisors were cleaned with saline and cut
from the jaw, rinsed with ice cold saline, and then cut
sagitally into two halves. Total RNA was extracted from
the pulp and odontoblasts with Trizol (Invitrogen, Carlsbad,
CA). Similarly, total RNA was extracted from brain and TG
using Trizol.Cell culture
Odontoblast-like MDPC-23 cells, derived from rodent
dental papilla cells, were kindly provided by Dr. Moon-Il
Cho, from the School of Dental Medicine, State Univer-
sity of New York, Buffalo, NY. MDPC-23 cells were cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM,
Invitrogen, Carlsbad, CA), supplemented with 10% fetal
bovine serum (Hyclone Laboratories, Logan, UT), peni-
cillin, and streptomycin (Invitrogen, Carlsbad, CA) at 5%
CO2 in a 37°C incubator. MDPC-23 cells were treated in
DMEM without serum with DMSO (vehicle), TGF-β1
(1 and 10 ng/ml), SB431542 (0.1, 1, and 10 μM), TGF-β1
(1 ng/ml) plus SB431542 (10 μM), roscovitine (25 μM), and
TGF-β1 (1 ng/ml) plus roscovitine (25 μM) at different time
points, and total RNA or protein extracts were obtained for
qPCR or Western blot analysis, respectively. For differenti-
ation studies, MDPC-23 cells were cultured in complete
medium (DMEM plus 10% FBS) supplemented with ascor-
bate (50 μg/ml) and β-glycerophosphate (10 mM) over
5 days. The medium was changed every 2 days as reported
earlier [23].RNA isolation
Total RNA using TRIzol® reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instructions was
obtained from mouse tissues (Odontoblast-enriched pre-
paration, TG, and brain) or from MDPC-23 cells treated
with DMSO (vehicle), TGF-β1 (1 ng/ml), SB431542
(10 μM), and TGF-β1 (1 ng/ml) plus SB431542 (10 μM)
during 0, 1, 2, and 3 h in serum-free medium. Following
TURBO DNA-free (Ambion, Austin, TX) digestion of the
total RNA sample, oligo (dT) primed synthesis of cDNA
from 3 μg of total RNA was made using SuperScript™ III
Reverse Transcriptase (Invitrogen, Carlsbad, CA) to re-
move contaminated genomic DNA.
Figure 6 Proposed model illustrating the participation of Cdk5 in signaling pathways that influence dental nociception. Bacterial
inflammation occurring in dental caries increases secretion of TGF-β1 into the extracellular matrix, which in turn activates Smad dependent and
independent pathways in odontoblast cells. These cascades activate Cdk5 activity by increasing Egr-1 and p35 expression. Then, the Cdk5/p35
complex phosphorylates TRPV1, resulting in enhanced calcium influx and the subsequent activation of action potentials, which in turn may
increase transmitter release. Pain transmission would occur through transmitter-mediated activation of pulpal neurons. Moreover, Cdk5 may
modulate the sensitivity of other nociceptors such as TRPA1, TRPM8, or TREK-1 during inflammation-induced tooth pain.
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For detection of Cdk5, p35, and Egr-1 mRNA from
MDPC-23 cells, we used qPCR. The following reaction
mixture was used for these PCR samples: 1xIQ™
Sybr®Green Super Mix (Bio-Rad, Hercules, CA), 100–
200 nM of each primer and 1 μl of cDNA. cDNA was
amplified and analyzed in triplicate using Opticon Moni-
tor Chromo 4 (Bio-Rad, Hercules, CA). The following
primers were used to amplify and measure the amount
of mouse mRNA by qPCR: Cdk5 sense 5′-GGC TAA
AAA CCG GGA AAC TC-3′ and antisense 5′-CCA
TTG CAG CTG TCG AAA TA-3′; p35 sense 5′-GCC
CTT CCT GGT AGA GAG CTG-3′ and antisense 5′-
GTG TGA AAT AGT GTG GGT CGG C-3′; Egr-1
sense 5′-CCC TTC CAG GGT CTG GAG AAC CGT-3′
and antisense 5′-GGG GTA CTT GCG CAT GCG GCT
GGG-3′. The gene expression level was normalized
against S29 expression using these primers: S29 sense
5′-GGA GTC ACC CAC GGA AGT TCG G-3′ and
antisense 5′-GGA AGC ACT GGC GGC ACA TG-3′.
qPCR samples were run in triplicate each and reaction was
repeated three times.Conventional RT-PCR
For detection of Cdk5, p35, Tau, DSPP, DMP1, and
TRPV1 mRNA from mouse tissues, we used conven-
tional RT-PCR. The reaction mixture was used for these
PCR samples: Buffer Taq 10X, MgCl2 2 mM, dNTPs
0.2 mM, and 10 μM of each primer and 4 μl of cDNA.
The PCR was performed using Taq (Thermo Scientific)
according to the following condition: 5 min hot start at
94°C, 35 cycles of 30 s at 94°C, 30 s at 57-60°C (depend-
ing each pair of primers), and 1 min at 72°C, and 10 min
at 72°C final extension. The primers used for Cdk5 and
p35 were the same that used in PCR. The amplicon size
was 228 bp for Cdk5 and 113 bp for p35. Primers for
odontoblast markers (DSPP and DMP1) were: DSPP
sense 5′-ATT CCG GTT CCC CAG TTA GTA-3′ and
DSPP antisense 5′- CTG TTG CTA GTG GTG CTG
TT-3′ (108 bp amplicon size); DMP1 sense 5′-GTG
CCC AAG ATA CCC CCA G-3′ and antisense 5′-GCA
TCC CTT CAT CAT CGA ACT CA-3′ (147 bp
amplicon size). Primers for Tau (neuronal marker) were
Tau sense 5′- CTG AAG CAC CAG CCA GGA GG-3′
and Tau antisense 5′-TGG TCT GTC TTG GGT TTG
GC-3′ (368 bp amplicon size). Finally, primers for
TRPV1 were TRPV1 sense 5′-CCC TCC AGA CAG
AGA CCC TA-3′ and TRPV1 antisense 5′-AGC TGA
CGG TGA TGA TAG GG-3′ (171 bp amplicon size).
The gene expression level was normalized against
S29 expression using primers described above in
the qPCR section. PCR products were run in 2%
agarose gel.Transient transfection
CMV-TRPV1-GFP plasmid (33) was transiently transfected
into MDPC-23 cells using Lipofectamine™ LTX and Plus™
Reagent (Invitrogen, Carlsbad, CA) for 48 h. After 24 h of
transfection, MDPC-23 cells were treated with TGF-β1
(1 ng/ml), SB431542 (10 μM), and TGF-β1 (1 ng/ml) plus
SB431542 (10 μM) over 24 h and then proteins were
extracted for Western blot analysis.
Immunoblot analysis
MDPC-23 cells were treated with DMSO (vehicle), TGF-
β1 (1 ng/ml), SB431542 (10 μM), TGF-β1 (1 ng/ml) plus
SB431542 (10 μM), TGF-β1 (1 ng/ml) plus U0126
(20 μM) for 0, 1, 2, 3, and 24 h in serum-free medium.
MDPC-23 cells were lysed in T-PER buffer (Pierce,
Rockford, IL) with protease inhibitor cocktail tablets
(Complete Mini) and phosphatase inhibitor cocktail tab-
lets, PhosSTOP (Roche Diagnostic, Indianapolis, IN).
Protein concentration in the supernatant was de-
termined using a Bradford Protein Assay (Bio-Rad,
Hercules, CA). Proteins were separated in 4-12% or
3-8% SDS-PAGE gels and transferred to nitrocellulose
membranes (Invitrogen, Carlsbad, CA). The membranes
were soaked in a blocking buffer (5% nonfat dry milk in
phosphate-buffered saline with 0.05% Tween-20 (PBST))
for 1 h at room temperature, and then incubated over-
night at 4°C with the appropriate primary antibody
diluted in the blocking buffer. The membranes were
washed in PBST and incubated for 1 h at room tem-
perature with the secondary antibodies diluted in
blocking buffer. Immunoreactivity was detected by
SuperSignal West Pico or Dura Chemiluminescent Sub-
strate (Thermo Scientific, Rockford, IL). Membranes
were stripped for 15 min at room temperature with Re-
blot Plus Strong Solution (Chemicon, Temecula, CA)
and retested with α-tubulin antibodies to normalize for
protein loading. The optical densities of the bands were
quantified using an image analysis system with Scion
Image Alpha 4.0.3.2 software (Scion Corporation,
Frederick, MD).
Cdk5 kinase activity assay
Cdk5 kinase activity was measured using 250 μg of pro-
tein from MDPC-23 cells treated with either vehicle,
TGF-β1 (1 and 10 ng/ml), SB431542 (0.1, 1, 10 μM),
TGF-β1 (1 ng/ml) plus SB431542 (10 μM), roscovitine
(25 μM), or TGF-β1 (1 ng/ml) and roscovitine (25 μM)
over 24 h. Proteins were dissolved in T-PER buffer and
immunoprecipitated using 4 μg of anti-Cdk5 antibody
C8 (Santa Cruz, CA). Immunoprecipitated proteins (IP)
were washed 3 times in cold PBS, and 2 times in kinase
buffer [20 mM Tris HCl (pH 7.4), 10 mM MgCl2 and
1 mM EDTA]. IP were then mixed with the kinase assay
mixture [100 mM Tris · HCl (pH 7.4), 50 mM MgCl2,
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with 5 μg of Histone H1 used as a substrate. Kinase as-
says were carried out at 30°C for 30 min and the kinase
activity reaction was stopped by adding 5xSDS sample
buffer and boiling it for 10 min at 70°C. The kinase reac-
tion was electrophoresed on a 4-20% polyacrylamide gel
and then gels were exposed to X-ray films for 1–3 h
at −80°C. The incorporation of P32 to Histone H1 was
quantified to measure band intensity using Scion Image
Alpha 4.0.3.2 software (Scion Corporation, Frederick, MD).
MDPC-23 TRPV1 Cell Line
MDPC-23 cells were transfected with rat TRPV1 cDNA in
the pεMTH vector [33] and stable clones were generated
after G418 selection (800 μg/ml). Individual clones were
screened for TRPV1 activity using calcium imaging and
capsaicin stimulation, as described previously [15]. MDPC-
23 TRPV1 cells were maintained in high-glucose DMEM
(Invitrogen) supplemented with 5% heat-inactivated horse
serum (Invitrogen), GlutaMAX (Invitrogen), pen-strep
(Invitrogen), Normocin (Invivogen), and G418 (200 μg/ml)
to maintain TRPV1 selection. For calcium-uptake assays,
cells were plated onto poly-D-lysine coated 96-well plates
at a density of 30,000 cells/well. TGF-β1, SB431542, and
roscovitine were added after 24 h in culture, when the cells
were ~100% confluent. Cells were incubated for an add-
itional 24 h then assayed for TRPV1 activity.
Assay buffers
The buffer used for 45Ca2+ uptake assays contained
140 mM NaCl, 5.33 mM KCl, 0.1 mM CaCl2, and 2.8 mM
MgCl2, and were supplemented with 10 mM Glucose and
26.5 mM Sucrose. The pH was adjusted to 7.4 by the
addition of 10 mM HEPES, and 1 mM Ascorbic acid was
added to buffers containing capsaicin to prevent oxidation.
For 45Ca2+ uptake assays using proton-rich environments,
an unbuffered assay buffer was prepared that contained
140 mM NaCl, 5.33 mM KCl, 0.1 mM CaCl2, and 2.8 mM
MgCl2, and was supplemented with 10 mM Glucose and
26.5 mM Sucrose (no buffering agent was added). The pH
was set to 5.6 by the addition of 15 mM MES hydrate and
5 mM MES Na salt to the unbuffered assay buffer. Lysis
buffer was made by diluting stock solutions of 10 M
Triton-X-100 and 10 M SDS in ultrapure water to make a
final solution containing 1% Triton-X-100 and 1% SDS.
45Ca2+ uptake assay
All 45Ca2+ uptake assays followed the same protocol and
were piloted by a Biomek FX liquid handling robot
(Beckman Coulter), which was used in all assays. It was
programmed to dilute drugs with 45Ca2+-containing
(0.4 μCi/well) assay buffer on a separate 96-well plate
(Evergreen Scientific) in a total volume of 75 μl/well, re-
move cell culture medium, wash cells with assay buffer,simultaneously transfer drugs and 45Ca2+ to each well on
a 96-well plate, allow for an incubation period of 5 to
8 min. at room temperature, remove 45Ca2+ and drugs,
wash cells with assay buffer, lyse cells in lysis buffer and
transfer lysate to a 96-well OptiPlate (white, PerkinElmer
Life and Analytical Sciences) preloaded with 125 μl of
MicroScint-40 (PerkinElmer Life and Analytical Sciences)
scintillation liquid. For manipulations containing assay
buffer with a pH of 5.6 or capsaicin, the same protocol
was used, however the capsaicin and acidic solutions were
preloaded into 45Ca2+ rich assay buffers to allow for simul-
taneous transfer. A control capsaicin dose–response dilu-
tion was performed on each 96-well plate, along with the
treatment, to allow for normalization and to check con-
sistency between experiments. A liquid scintillation coun-
ter (TopCount NX, PerkinElmer Life and Analytical
Sciences) was used to quantify the 45Ca2+ signal for fur-
ther analysis.Statistical analysis
All experiments were performed a minimum of 3 times.
Statistical evaluation was done with GraphPad Prism
software, version 4.0 (GraphPad, San Diego, CA). Signifi-
cant differences between the experiments were assessed
by univariate ANOVA (more than 2 groups) or unpaired
t-tests (2 groups). ANOVA was followed by t-tests using
a Bonferroni α-correction or Dunnett’s test, where α was
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